



Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study

OPEN ACCESS

Edited and Reviewed by:

Matteo Bellone,
San Raffaele Hospital
(IRCCS), Italy

*Correspondence:

Maria Pia Pistillo
mariapia.pistillo@hsanmartino.it

Specialty section:

This article was submitted
to Cancer Immunity and
Immunotherapy,
a section of the journal
Frontiers in Immunology

Received: 15 January 2018

Accepted: 13 February 2018

Published: 02 March 2018

Citation:

Queirolo P, Dozin B, Morabito A,
Banelli B, Piccioli P, Fava C, Leo C,
Carosio R, Laurent S, Fontana V,
Ferrucci PF, Martinoli C,
Cocorocchio E, Battaglia A,
Ascierto PA, Capone M, Simeone E,
De Galitiis F, Pagani E,
Antonini Cappellini GC, Marchetti P,
Guida M, Tommasi S, Mandalà M,
Merelli B, Quaglino P, Fava P,
Guidoboni M, Romani M, Spagnolo F,
and Pistillo MP (2018) Corrigendum:
Association of CTLA-4 Gene Variants
with Response to Therapy and
Long-term Survival in Metastatic
Melanoma Patients Treated with
Ipilimumab: An Italian Melanoma
Intergroup Study.
Front. Immunol. 9:403.
doi: 10.3389/fimmu.2018.00403

Paola Queirolo¹, Beatrice Dozin², Anna Morabito³, Barbara Banelli^{3,4}, Patrizia Piccioli⁵,
Cristiana Fava¹, Claudio Leo¹, Roberta Carosio³, Stefania Laurent⁶, Vincenzo Fontana²,
Pier Francesco Ferrucci⁷, Chiara Martinoli⁷, Emilia Cocorocchio⁷, Angelo Battaglia⁷,
Paolo A. Ascierto⁸, Mariaelena Capone⁸, Ester Simeone⁸, Federica De Galitiis⁹,
Elena Pagani⁹, Gian Carlo Antonini Cappellini⁹, Paolo Marchetti^{9,10}, Michele Guida¹¹,
Stefania Tommasi¹¹, Mario Mandalà¹², Barbara Merelli¹², Pietro Quaglino¹³, Paolo Fava¹³,
Massimo Guidoboni¹⁴, Massimo Romani³, Francesco Spagnolo¹, and Maria Pia Pistillo^{3*}
On Behalf of the Italian Melanoma Intergroup (IMI)

¹ Department of Medical Oncology, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy,

² Unit of Clinical Epidemiology, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy,

³ Unit of Tumor Epigenetics, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy,

⁴ Department of Health Sciences, University of Genova, Genova, Italy, ⁵ Unit of Cellular Biology, IRCCS AOU San Martino-

IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, ⁶ Intergroup Melanoma Italiano (IMI) and Department of
Internal Medicine, University of Genova, Genova, Italy, ⁷ Oncology of Melanoma Unit, European Institute of Oncology, Milan,
Italy, ⁸ Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione 'G. Pascale',
Naples, Italy, ⁹ Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy, ¹⁰ Medical Oncology, Sant'Andrea Hospital,
Sapienza University of Rome, Rome, Italy, ¹¹ Department of Medical Oncology, Molecular Genetics Laboratory, IRCCS Istituto

Tumori "Giovanni Paolo II," Bari, Italy, ¹² Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni
XXIII Hospital, Bergamo, Italy, ¹³ Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy,

¹⁴ Immunotherapy and Cell Therapy, IRCCS-IRST, Meldola, Italy

Keywords: CTLA-4 variants, melanoma, ipilimumab, best overall response, overall survival, predictive/prognostic factor

A corrigendum on

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
by Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, et al. *Front Immunol* (2017) 8:386.
doi: 10.3389/fimmu.2017.00386

In the original article, affiliation number 9 was wrong. The correct affiliation 9 is "Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy". This error does not change the scientific conclusions of the article in any way.

The original article has been updated.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Queirolo, Dozin, Morabito, Banelli, Piccioli, Fava, Leo, Carosio, Laurent, Fontana, Ferrucci, Martinoli, Cocorocchio, Battaglia, Ascierto, Capone, Simeone, De Galitiis, Pagani, Antonini Cappellini, Marchetti, Guida, Tommasi,

Mandalà, Merelli, Quaglino, Fava, Guidoboni, Romani, Spagnolo and Pistillo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.